Global Down Syndrome

Issue 1 of 4 - 2018

Issue link: https://viewer.e-digitaledition.com/i/960711

Contents of this Issue

Navigation

Page 10 of 31

UNCOVERING THE ROLE OF CEREBRAL AMYLOID ANGIOPATHY IN ADULTS WITH DOWN SYNDROME A growing body of research points to an association between Alzheimer's disease and cerebral amyloid angiopathy (CAA), a problem that occurs when amyloid protein builds up within the walls of the arteries in the brain. According to research from the University of Kentucky and University of California, Irvine, adults with Down syndrome are 1.21 times more likely than typical adults with Alzheimer's disease to have CAA and 4.6 times more likely to have CAA than typical adults who don't have Alzheimer's disease. The researchers concluded that developing therapies that target CAA in Down syndrome may be useful in the continued search for Alzheimer's disease treatments. Acta Neuropathologica Communications, DECEMBER 2017 CHILDHOOD LEUKEMIA SURVIVORSHIP IN CHILDREN WITH DOWN SYNDROME Kids with Down syndrome have a much higher risk of developing certain types of leukemia. However, once their cancers have been successfully treated, these children have a lower likelihood of developing second cancers than their typical peers. This is just one way survivorship may differ in children with Down syndrome, according to research from UCSF Benioff Children's Hospital San Francisco. Investigators found that, with few exceptions, the risk of developing at least one chronic condition related to leukemia treatment is similar in children with Down syndrome and typical kids. Those with Down syndrome, however, are more likely than typical people to develop cataracts, hearing loss, and thyroid disorders after completing leukemia treatment. Whether these conditions are a result of treatment or a result of Down syndrome warrant further study. Cancer, NOVEMBER 2017 ESTROGEN, DOWN SYNDROME, AND ALZHEIMER'S DISEASE ONSET Women with Down syndrome go through menopause at earlier ages and have lower postmenopausal levels of bioavailable estradiol — factors that may increase overall dementia risk, according to this review. Furthermore, clinical trials testing estrogen replacement therapy (ERT) in postmenopausal women with Down syndrome may offer clarity about whether the therapy can help prevent or delay Alzheimer's disease. Women with Down syndrome have shorter intervals between menopause and signs of cognitive decline than typical women do, so studying the efficacy of ERT may be easier in this population. If results are promising, taking ERT in the years leading up to menopause may help women with Down syndrome better manage their Alzheimer's disease risk. Free Radical Biology and Medicine, AUGUST 2017 GLOBAL'S TESTIMONY At the hearing, Reps. Tom Cole (R-OK) and Rosa DeLauro (D-CT) recognized Michelle Sie Whitten, President and CEO of the Global Down Syndrome Foundation, as working hard to have "enormous impact on the lives of people with Down syndrome through research and medical care." Whitten's parents, children, and in-laws were also at the hearing. Rep. Cathy McMorris Rodgers (R-WA) used Global's science as a great example of innovative research despite lack of National Institutes of Health (NIH) funding. Whitten explained the financial trends. "From 2001 to 2017, if the Down syndrome research budget increased at the same rate as the NIH budget — up or down — we would be at $744 million in total research today," Whitten said. "Over those two decades, we've hit about $350 million." "Today, we're ready to work with a trans-NIH platform that builds on these amazing breakthroughs," Whitten continued. "The science and our families stand ready." "On behalf of my daughter's future, our constituents with Down syndrome and their families, and others who stand to gain from our science, we hope that Congress can help effectuate a trans-NIH approach to Down syndrome research," she said in closing. "Our children and adults with Down syndrome who are American citizens deserve to know that there is research funding and medical care available to them that allows them to reach their true potential." SCIENCE SNPs GLOBALDOWNSYNDROME.ORG 11

Articles in this issue

Links on this page

Archives of this issue

view archives of Global Down Syndrome - Issue 1 of 4 - 2018